1217 / 1241
A.
B.
C.
D.
11%
37%
47%
5%
Q3. Dose-painting trials
A. Could be performed on
any valuable metabolic
imaging
B. Should be performed with
metabolic imaging with a
predictive value for post-
radiotherapy relapse
C. Require quality control
D. Should be widely spread
whatever the risk of
« killing » the value of a
metabolic imaging
MR spectroscopic imaging for dose-painting
27